Mirum Pharmaceuticals, Inc.

Annual Trend FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Total revenue $2.2m $0 $19.1m $77.1m $186.4m $336.9m $521.3m
Cost of sales $473k $0 $1.9m $12.4m $47.0m $81.6m $100.2m
Research and development $43.0m $81.6m $131.4m $106.8m $102.6m $140.6m $186.2m
Selling, general and administrative $59.2m $89.1m $145.9m $202.2m $257.0m
Total operating expenses $54.7m $104.3m $192.6m $208.3m $295.5m $424.5m $543.4m
Loss from operations ($54.7m) ($104.3m) ($173.4m) ($131.2m) ($109.2m) ($87.6m) ($22.1m)
Interest income $2.2m $1.6m $366k $3.9m $13.7m $13.8m $12.7m
Loss from termination of revenue interest purchase agreement $0 $0 ($49.1m) $0 $0
Loss before provision for income taxes ($52.5m) ($103.3m) ($84.0m) ($142.1m) ($162.4m) ($86.9m) ($21.4m)
Provision for income taxes $21k $6k $37k ($6.4m) $991k $1.0m $1.9m
Net loss ($52.6m) ($103.3m) ($84.0m) ($135.7m) ($163.4m) ($87.9m) ($23.4m)
Net loss per share, basic (in dollars per share) ($3) ($4) ($4) ($2) ($0)
Net loss per share, diluted (in dollars per share) ($5) ($4) ($3) ($4) ($4) ($2) ($0)
Weighted-average shares of common stock outstanding, basic (in shares) 30.3m 33.8m 40.9m 47.5m 50.2m
Weighted-average shares of common stock outstanding, diluted (in shares) 30.3m 34.0m 40.9m 47.5m 50.2m
Interest expense $0 ($335k) ($17.6m) ($16.0m) ($15.1m) ($14.3m) ($14.4m)
Other income (expense), net ($21k) ($192k) ($582k) $365k ($2.8m) $1.2m $2.4m